Baxter International (BAX) recently cut its quarterly dividend from $0.17 per share to a token penny, shifting the stock away from income appeal and putting more cash back into the business.

The dividend cut comes after a strong 90 day share price return of 22.42% and an 11.44% year to date share price gain. However, the 1 year total shareholder return of 27.75% and 5 year total shareholder return of 69.29% both remain sharply negative, suggesting recent momentum contrasts with a much tougher longer term experience for investors.

If this reset at Baxter has you rethinking where you want growth and income to come from, it could be a good moment to scan 26 healthcare AI stocks for other healthcare names catching attention.

So, with Baxter trading close to both its analyst target and one estimate of intrinsic value after a sharp short-term rebound, is the turnaround still underappreciated by the market, or is future growth already priced in?

Most Popular Narrative: 6.1% Undervalued

With Baxter International closing at $21.73 against a widely followed fair value narrative of about $23.13, the story hinges on whether execution catches up with these assumptions.

Baxter's strengthened focus on innovation including new product launches in advanced infusion systems, AI-enabled devices, and compounding aligns with growing demand for efficient, digitalized, and connected healthcare equipment. This positions the company to capture higher-margin revenue streams and gain market share. An aging population and the rising prevalence of chronic diseases are long-term drivers of increased demand for Baxter's critical care, compounding, and advanced surgery products, supporting sustained top-line growth as these demographic shifts accelerate healthcare utilization.

Curious what assumptions sit behind that fair value gap? The narrative leans heavily on a step up in revenue, a swing into profitability, and a richer earnings multiple. The exact hurdle rates and timeline might surprise you.

Result: Fair Value of $23.13 (UNDERVALUED)

However, that story can break if IV fluid usage stays 20% below historical norms, or if further Novum IQ quality setbacks keep pressure on volumes and margins.

Build Your Own Baxter International Narrative

If you see the Baxter story differently, or simply prefer to test your own assumptions against the data, you can build a custom view in just a few minutes: Do it your way

A great starting point for your Baxter International research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.

Ready to hunt for your next idea?

If Baxter has you thinking harder about risk, income, and upside, do not stop here. Widen your search with data driven stock ideas tailored to different goals.

• Target value opportunities by scanning 53 high quality undervalued stocks that combine solid fundamentals with prices that may not fully reflect their financial profile.
• Prioritize resilience by checking 83 resilient stocks with low risk scores built around companies with lower risk scores for steadier portfolio building blocks.
• Get ahead of the crowd by exploring our screener containing 24 high quality undiscovered gems that highlight quality names many investors may not be watching yet.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.